Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice
Conclusion: NSCLC patients treated with nivolumab as second-line therapy had a longer PFS compared to patients treated with docetaxel in a health care environment.Chemotherapy 2017;62:374-380
Source: Chemotherapy - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Environmental Health | Health Management | Lung Cancer | Non-Small Cell Lung Cancer | Statistics | Study | Taxotere